Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF-003 in ROSAH Syndrome Patients
NCT06395285Phase 1Recruiting
- Sponsor
- Drug Farm
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of DF-003 in Retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache syndrome, sponsored by Drug Farm. Primary endpoints: Treatment-Emergent Adverse Events and Serious Adverse Events. Started May 2025; status: recruiting.
02
Drugs
DF-003
03
Conditions
Retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache syndrome
Beyond the preview
Go deeper on NCT06395285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395285.